The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a more substantial decreas